Search

everythinglearnresearchcommunity

for

Search:↓

Hair transplant after 1 year shows great results. Treatment done in Turkey, patient from Pakistan living in Germany.

A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

Using finasteride before a hair transplant can prevent further hair loss and make the transplant look more natural. Patients should continue using finasteride until hair cloning becomes available.

A 42-year-old with a Norwood 2 hairline is using topical minoxidil and finasteride with tretinoin to address hair loss, having previously experienced side effects from oral finasteride and dutasteride. Suggestions include continuing current treatments, considering microneedling, and being patient for results.

A 31-year-old man has been using Dutasteride since 2022, alongside topical Minoxidil, with positive results and no issues. His new healthcare provider expressed concerns about long-term Dutasteride use and suggested alternatives like oral Minoxidil and Spironolactone, but the patient is hesitant to change a successful routine.

The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.

The user is using a regimen of 0.5mg dutasteride, 5% minoxidil foam at night, hair gummies, and rosemary water in the morning to address hair loss. They are experiencing some regrowth and are advised to be patient, with suggestions to possibly increase minoxidil application to twice a day for better results.

The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.

A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.

The user has been dealing with hair loss for 10 years, worsened by psoriasis, and uses minoxidil and finasteride. They seek advice on managing psoriasis and hair loss, with suggestions to see a dermatologist, try different shampoos, and be patient.

The user has experienced significant hair regrowth in 4 months using oral minoxidil, oral finasteride, and 2% ketoconazole cream. They are advised to continue the treatment, keep hair short, and be patient for further progress.

A 23-year-old with diffuse thinning for 2 years is using Finasteride 1mg, prescribed by a dermatologist, and is seeking advice on regrowth expectations. Replies suggest continuing Finasteride, possibly adding Minoxidil, and being patient with results.

A 30-year-old man has been using Minoxidil for years with limited success and recently started Finasteride, experiencing minor side effects but hoping for regrowth. Other users suggest not overthinking, considering a buzz cut, and being patient for results.

User is depressed about hair loss despite using topical minoxidil for 5 months and topical finasteride for 2 months, with no improvement. Others suggest trying oral finasteride, seeing a specialist for dandruff and oily scalp, and being patient.

The user had a detailed 3.5-hour consultation with Dr. Zarev for hair loss treatment, praising his meticulous approach and innovative techniques, and was prescribed topical finasteride and minoxidil. Other users agreed on Zarev's expertise, noting his long waiting list and the high quality of his work, with one surgery per week and a focus on individual patient care.

The conversation is about the effectiveness of finasteride (fin) in preventing hair loss after a hair transplant. Some users have experienced hair thinning and loss after stopping finasteride, while others have had success with finasteride and minoxidil (min) in maintaining their transplanted hair. The general consensus is that finasteride is important for younger patients to prevent further hair loss.

The user is considering adding a scalp massager to their current hair loss treatments, which include finasteride, minoxidil, pumpkin seed oil, and microneedling. They are seeking advice on whether to invest in a scalp massager or remain patient with their current regimen.

Asian dermatologists are more open to prescribing finasteride, while in some regions, medications like finasteride and minoxidil can be obtained without a prescription. In Europe, particularly France, there are stricter regulations requiring patients to acknowledge potential side effects, but many people find ways to obtain these treatments through various means.

RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.